• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5036585)   Today's Articles (444)
For: Gilbert PB. Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. Stat Med 2010;29:1061-71. [PMID: 20419758 PMCID: PMC2929839 DOI: 10.1002/sim.3676] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Number Cited by Other Article(s)
1
Zolla-Pazner S, Gilbert PB. Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial. J Virol 2019;93:e00629-19. [PMID: 31189712 PMCID: PMC6694814 DOI: 10.1128/jvi.00629-19] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]  Open
2
Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. Lancet HIV 2019;6:e475-e482. [PMID: 31078451 DOI: 10.1016/s2352-3018(19)30133-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 02/28/2019] [Accepted: 03/25/2019] [Indexed: 12/12/2022]
3
Gilbert PB. Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. ACTA ACUST UNITED AC 2019;11. [PMID: 33312415 DOI: 10.1515/scid-2019-0003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
4
Feller C, Schorning K, Dette H, Bermann G, Bornkamp B. Optimal designs for dose response curves with common parameters. Ann Stat 2017. [DOI: 10.1214/16-aos1520] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
5
Methodical Considerations. HUMAN VACCINES 2017. [DOI: 10.1016/b978-0-12-802302-0.00006-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
6
Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. STATISTICAL COMMUNICATIONS IN INFECTIOUS DISEASES 2017;9:20160001. [PMID: 29218117 PMCID: PMC5714515 DOI: 10.1515/scid-2016-0001] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
7
Richert L, Lhomme E, Fagard C, Lévy Y, Chêne G, Thiébaut R. Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother 2016;11:1022-9. [PMID: 25751670 DOI: 10.1080/21645515.2015.1011974] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]  Open
8
Hey SP, Kimmelman J. Ethics, error, and initial trials of efficacy. Sci Transl Med 2013;5:184fs16. [PMID: 23658242 DOI: 10.1126/scitranslmed.3005684] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
9
Dette H, Kiss C, Benda N, Bretz F. Optimal designs for dose finding studies with an active control. J R Stat Soc Series B Stat Methodol 2013. [DOI: 10.1111/rssb.12030] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
10
Taylor DJ, Grobler A, Abdool Karim SS. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. Clin Trials 2012;9:377-84. [DOI: 10.1177/1740774512445512] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
11
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. ACTA ACUST UNITED AC 2012;2:245-254. [PMID: 23243491 DOI: 10.4155/cli.12.8] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
12
Nam JS, Kang SH. Statistical Consideration of Vaccine Clinical Trials. KOREAN JOURNAL OF APPLIED STATISTICS 2011. [DOI: 10.5351/kjas.2011.24.4.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
13
Excler JL, Rida W, Priddy F, Gilmour J, McDermott AB, Kamali A, Anzala O, Mutua G, Sanders EJ, Koff W, Berkley S, Fast P. AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses 2011;27:669-80. [PMID: 21043994 PMCID: PMC3101085 DOI: 10.1089/aid.2010.0206] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]  Open
14
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. ACTA ACUST UNITED AC 2011. [PMID: 23181167 DOI: 10.2202/1948-4690.1037] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
15
Zhang M, Gilbert PB. Increasing the Efficiency of Prevention Trials by Incorporating Baseline Covariates. STATISTICAL COMMUNICATIONS IN INFECTIOUS DISEASES 2010;2:1. [PMID: 21152074 PMCID: PMC2997740 DOI: 10.2202/1948-4690.1002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA